Ispronicline

Ispronicline
Clinical data
ATC code
  • none
Identifiers
  • (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H22N2O
Molar mass234.343 g·mol−1
3D model (JSmol)
  • C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
  • InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1 X markN
  • Key:RPCVIAXDAUMJJP-PZBABLGHSA-N X markN
 X markNcheckY (what is this?)  (verify)

Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.

It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms

Ispronicline is subtype-selective, binding primarily to the α4β2 subtype. It has antidepressant, nootropic and neuroprotective effects.[medical citation needed]

Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache. However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.

See also